Sionna Therapeutics (SION) Jefferies Global Healthcare Conference 2026 summary

Strategic vision and market opportunity

• Focus on transforming cystic fibrosis (CF) treatment by targeting the NBD1 region of the CFTR protein, aiming to address the significant unmet need where only one-third of patients on current therapies reach normal CFTR function.

• The CF market is valued at $12–13 billion and is projected to exceed $15 billion by the end of the decade, with a monopoly currently held by a single competitor.

• Sionna’s approach leverages a rich scientific history, originating from Genzyme and Sanofi, and focuses on differentiated NBD1 stabilizers.

Scientific and clinical development

• NBD1 stabilizers are designed to directly address the F508del mutation, present in 90% of CF patients, by stabilizing the NBD1 domain and improving protein function beyond current standards.

• Preclinical data show that NBD1 monotherapy can match the efficacy of current triple combinations, and dual combinations may drive more patients to normal CFTR function.

• Two lead compounds, SION-719 and SION-451, are advancing in parallel: 719 as an add-on to standard care and 451 as the anchor in dual combinations.

• Both programs are expected to deliver key data in summer 2026, with SION-719 in the PreciSION CF proof-of-concept study and SION-451 in phase I dual combination studies.

• The company is well-capitalized with $290 million in cash, providing runway into 2028.

Clinical strategy and decision points

• The PreciSION CF study is a two-way crossover trial designed to demonstrate at least a 10 millimole sweat chloride improvement, which is expected to translate into a clinically meaningful FEV1 gain.

• Patient enrollment criteria exclude those already at normal sweat chloride or with atypically high levels, focusing on those with typical responses to current therapy.

• Two strategic decisions are planned for summer 2026: selecting the optimal dual combination for further development and determining whether to advance the add-on approach based on data and available capital.

• Both strategies are considered commercially viable and have received positive feedback from the patient and investor communities.